文献速递免疫规划卫生政策与健康促进

评估澳大利亚儿童免疫规划中引入20价肺炎球菌结合疫苗的实施效果

Evaluating the implementation of the 20-valent pneumococcal conjugate vaccine for paediatric immunization in Australia.
PubMed 文献 · Vaccine · 2025-11-19

该成本效果分析从支付方视角,采用基于人群的多队列模型(10年时间 horizon,成本和收益年贴现率5%),比较澳大利亚儿童国家免疫规划(NIP)中引入PCV20与现行PCV13及可用但未获资助的PCV15的公共卫生和经济影响。模型估计PCV20较PCV13和PCV15可预防更多疾病病例和死亡,并获得更多QALY和总成本节约,因此PCV20为优势策略。

要点

  • PCV20较PCV13和PCV15在10年内可预防更多肺炎球菌疾病病例和死亡。
  • PCV20较PCV13和PCV15分别获得QALY增益并节约总成本,为优势策略。
  • 概率敏感性分析中PCV20在多数迭代中仍为优势策略。

核心结论

  • 该成本效果分析估计,将PCV20纳入澳大利亚儿童NIP较PCV13和PCV15为优势策略,带来健康获益和成本节约。

研究设计与样本

  • 从支付方视角开展的成本效果分析,使用基于人群的多队列模型,时间范围为10年,成本和收益年贴现率为5%。
  • 模型考虑接种疫苗的<2岁队列的直接疫苗效应和所有年龄未接种者的间接效应。
  • 流行病学、成本和效用输入数据来自澳大利亚特定来源;疫苗有效性输入来自PCV13真实世界有效性数据、PCV7效力数据和PCV13影响数据。
  • 模型估计每种疫苗接种策略的肺炎球菌疾病病例(侵袭性肺炎球菌病、肺炎和中耳炎)、死亡、成本和QALY,用于计算增量成本效果比;并进行敏感性分析。

主要发现

  • 模型估计,10年内PCV20较PCV13可预防更多疾病病例和死亡(分别为642,804例和8,308例),较PCV15可预防更多疾病病例和死亡(分别为290,943例和3,730例)。
  • PCV20较PCV13和PCV15分别获得QALY增益117,417和55,279,并分别节约总成本668,174,379澳元和312,296,604澳元。
  • 因此,PCV20预测较两种对照策略均为优势疫苗接种策略。
  • 在概率敏感性分析中,PCV20较PCV13在97.40%的迭代中为优势策略,较PCV15在85.70%的迭代中为优势策略。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In Australia, the paediatric national immunization programme (NIP) currently includes 13-valent pneumococcal conjugate vaccine (PCV13) under 2 + 1 schedule. The 15-valent (PCV15) and 20-valent pneumococcal conjugate vaccines (PCV20) are available in Australia but not yet NIP funded. This cost-effectiveness analysis compared the public health and economic impact of implementing PCV20 into the Australian paediatric NIP versus PCV13 and PCV15. METHODS: We conducted the cost-effectiveness analysis from the payer perspective using a population-based multi-cohort model with a 10-year horizon and a 5 % annual discount rate for costs and benefits. The model considered direct vaccine effects in the vaccinated cohort aged <2 years and indirect effects in unvaccinated individuals of all ages. Input data for epidemiology, costs, and utilities were obtained from Australia-specific sources. Vaccine effectiveness inputs were derived from PCV13 real-world effectiveness data, 7-valent pneumococcal conjugate vaccine (PCV7) efficacy data, and PCV13 impact data. Model estimated pneumococcal disease cases (invasive pneumococcal disease, pneumonia, and otitis media), deaths, costs, and quality-adjusted life years (QALY) for each vaccination strategy, which were used to calculate incremental cost-effectiveness ratios. Sensitivity analyses were conducted to test uncertainty in input parameters and examine model robustness. RESULTS: Model estimated that PCV20 implementation would prevent more disease cases and deaths than PCV13 (642,804 and 8308, respectively) and PCV15 (290,943 and 3730, respectively) over 10 years. PCV20 was associated with QALY gains of 117,417 and 55,279, and total cost-savings of AUD 668,174,379 and AUD 312,296,604 versus PCV13 and PCV15, respectively. Therefore, PCV20 was predicted to be the dominant vaccination strategy versus both comparators. PCV20 was also dominant versus PCV13 in 97.40 % of probabilistic sensitivity analysis iterations and versus PCV15 in 85.70 % of iterations. CONCLUSIONS: This cost-effectiveness analysis estimated that adoption of PCV20 into the Australian paediatric NIP would be dominant versus PCV13 and PCV15, leading to health benefits and cost-savings.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Struwig VA, Ta A, Thorat AV, et al. Evaluating the implementation of the 20-valent pneumococcal conjugate vaccine for paediatric immunization in Australia. Vaccine. 2025. PMID: 41265005. doi:10.1016/j.vaccine.2025.127996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。